Category: Post-hoc Analysis

Treatment of Moderate-to-severe Acne Vulgaris in a Hispanic Population: A Post-hoc Analysis of the Efficacy and Tolerability of Clindamycin 1.2%/ Benzoyl Peroxide 3.75% Gel

aAndrew F. Alexis, MD, MPH; bFran Cook-Bolden, MD; cTina Lin, PharmD aDepartment of Dermatology, Mount Sinai St. Luke’s and Mount Sinai West, New York, New York bSkin Specialty Dermatology and Department of Dermatology, Mount Sinai Health Systems, New York, New York cValeant Pharmaceuticals North America LLC, Bridgewater, New Jersey Disclosure: Dr. Alexis is an Advisory


Onychomycosis of Toenails and Post-hoc Analyses with Efinaconazole 10% Solution Once-daily Treatment Impact of Disease Severity and Other Concomitant Associated Factors on Selection of Therapy and Therapeutic Outcomes

James Q. Del Rosso, DO, FAOCD Clinical Professor (Dermatology), Adjunct Faculty, Touro University College of Osteopathic Medicine, Henderson, Nevada; Private Practice, Lakes Dermatology, Las Vegas, Nevada; Research Director, Del Rosso Dermatology Research Center, Las Vegas, Nevada Disclosure: Dr. Del Rosso serves as a consultant (C) and/or speaker?(S) for several companies that currently market and/or are


Clindamycin Phosphate 1.2%/ Tretinoin 0.025% Gel for the Treatment of Acne Vulgaris: Which Patients are Most Likely to Benefit the Most?

James Q. Del Rosso, DO, FAOCD Las Vegas Dermatology, Las Vegas, Nevada; Touro University College of Osteopathic Medicine, Henderson, Nevada DISCLOSURE OF COMPANY RELATIONSHIPS: Dr. Del Rosso serves as a consultant and speaker for Aqua, Anacor, Celgene, Ferndale, Innocutis, Promius, Unilever, and Valeant; he serves as a consultant, researcher, and speaker for Allergan, Galderma, LeoPharma,


Efficacy and Tolerability of a Fixed Combination of Clindamycin Phosphate (1.2%) and Benzoyl Peroxide (3.75%) Aqueous Gel in Moderate or Severe Adolescent Acne Vulgaris

Fran E. Cook-Bolden, MD Skin Specialty Dermatology, New York, New York Disclosure: Dr. Cook-Bolden was a principle investigator in the multicenter study and has been a consultant for Valeant Pharmaceuticals. Abstract Background: Acne is commonplace in adolescents and can be difficult to manage. Providing an effective and well-tolerated treatment may lead to improved adherence, increased